Tìm theo
Rimonabant
Các tên gọi khác (2) :
  • Acomplia
  • Rimonabant
Thuốc Gốc
Small Molecule
CAS: 158681-13-1
ATC: A08AX01
CTHH: C22H21Cl3N4O
PTK: 463.787
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C22H21Cl3N4O
Phân tử khối
463.787
Monoisotopic mass
462.078094435
InChI
InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
InChI Key
InChIKey=JZCPYUJPEARBJL-UHFFFAOYSA-N
IUPAC Name
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
Traditional IUPAC Name
rimonabant
SMILES
CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1
Độ hòa tan
2.00e-03 g/l
logP
5.91
logS
-5.4
pKa (strongest acidic)
12.42
pKa (Strongest Basic)
1.68
PSA
50.16 Å2
Refractivity
122.83 m3·mol-1
Polarizability
47.96 Å3
Rotatable Bond Count
4
H Bond Acceptor Count
3
H Bond Donor Count
1
Physiological Charge
0
Number of Rings
4
Bioavailability
1
Dược Lực Học : In the RIO-North America trial, 3040 patients were randomized to receive either placebo or one of two doses of rimonabant (5 mg or 20 mg per day). Patients taking 20 mg rimonabant had significant weigh loss, decrease in waist circumference, improved insulin sensitivity, and increases in HDL cholesterol, compared to patients on placebo.
Cơ Chế Tác Dụng : Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression. Rimonabant is a specific CB1 cannabinoid receptor antagonist. There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders.
Dược Động Học :
▧ Absorption :
Undetermined
▧ Protein binding :
Almost 100%
▧ Metabolism :
Hepatic, CYP3A4 involved.
▧ Half Life :
6 to 9 days with normal BMI and 16 days if BMI is greater than 30
Độc Tính : Almost twice as many people discontinued rimonabant compared with placebo because of adverse events (13.8% vs. 7.2%). These consistently involved psychiatric disorders (8.5% vs. 3.2%), including depression and anxiety. Other common side effects included insomnia, nausea, vomiting, diarrhoea and fatigue.
Chỉ Định : For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia.
Liều Lượng & Cách Dùng : Tablet, film coated - Oral
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Acomplia
  • Công ty :
    Sản phẩm biệt dược : Rimoslim
  • Công ty :
    Sản phẩm biệt dược : Riobant
  • Công ty :
    Sản phẩm biệt dược : Slimona
  • Công ty :
    Sản phẩm biệt dược : Zimulti
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB06155
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=104850
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=99443236
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C14319
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D05731
ChemSpider
http://www.chemspider.com/Chemical-Structure.94641.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21278
PharmGKB
http://www.pharmgkb.org/drug/PA152407999
Wikipedia
http://en.wikipedia.org/wiki/Rimonabant
Drugs.com
http://www.drugs.com/acomplia.html
... loading
... loading